#Japan #Tokyo #Lundbeck #migraine prevention #Eptinezumab

Lundbeck's Milestone in Migraine Treatment: Vyepti® Authorized in Japan

In a significant advancement for migraine patients, Lundbeck has secured marketing authorization for Vyepti® (eptinezumab) in Japan. Approved by the Ministry of Health, Labour and Welfare (MHLW), eptinezumab stands out as the sole intravenous (IV) CGRP-targeted preventive treatment for this debilitating condition. With its launch marking an important step for Lundbeck in Asia, it is already accessible in over 30 countries worldwide.

Migraine, a neurological disorder marked by severe headache attacks often accompanied by nausea and sensitivity to light and sound, affects approximately 8.4%–11.0% of the Japanese population. This translates to a major impact on daily life, resulting in significant economic losses estimated at $3 billion per year in Japan due to diminished productivity.

Tarek Samad, EVP and Head of Research and Development at Lundbeck, expressed pride and optimism regarding the approval, emphasizing its importance for patients who have long grappled with the challenges posed by migraines: "This approval represents a significant advancement for people living with migraine in Japan, where the disease continues to place a substantial burden on patients, families, and society."

The Clinical Backing of Eptinezumab

The green light for eptinezumab's marketing authorization was bolstered by two pivotal studies: the Phase III PROMISE-1 and PROMISE-2, which demonstrated the treatment's efficacy in episodic and chronic migraine respectively. Further examination in the Phase III SUNRISE trial focused specifically on a predominantly Asian demographic, leading to its official approval. Additionally, the safety of eptinezumab was addressed in a long-term extension study, SUNSET, conducted with Japanese patients, underscoring the commitment to local clinical insight and relevance.

This innovative treatment functions through the blockade of the calcitonin gene-related peptide (CGRP), which plays a crucial role in the pathophysiology of migraine. As a humanized monoclonal antibody designed for IV administration, eptinezumab delivers a targeted approach to migraine management, offering patients an option that aligns with modern therapeutic standards.

A New Era for Lundbeck in Japan

This approval is not merely a milestone for the migraine field; it also signifies Lundbeck's first independent commercial launch in Japan after 25 years of fostering patient-centric initiatives. With roots deeply embedded in brain health, Lundbeck is eager to expand its operational capacity in Japan, further delivering transformative solutions to those in need.

The effects of migraines extend far beyond physical pain. They disrupt normal routines, hinder work performance, and impact personal relationships, illustrating a dire need for effective management strategies. Lundbeck's proactive stance in the Japanese market reaffirms its resolve to tackle such pervasive health challenges.

As patients in Japan gain access to eptinezumab, Lundbeck's robust commitment to advancing brain health stands to improve the quality of life for many who face the trials of migraine. With comprehensive clinical backing and local relevance, eptinezumab's launch marks a pivotal moment not only for Lundbeck but for millions battling the invisible burden of migraines worldwide.

Conclusion

With the authorization of Vyepti®, Lundbeck is poised to play a critical role in not just alleviating migraine symptoms but in enriching lives through better management of this neurological disorder. As these efforts unfold, the hope is that patients will find a renewed sense of normalcy and productivity, ultimately aiding society as a whole in mitigating the socio-economic effects of migraines.